The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
Open accessAbstract
Despite recent advances in the treatment of multiple myeloma (MM), including proteasome inhibitors and immunomodulatory agents, patients invariably relapse and alternative treatment strategies are urgently needed. Bcl-2 inhibitors such as ABT-737 and ABT-263 (navitoclax), which target specifically anti-apoptotic proteins Bcl-2 and Bcl-x L , bring new hope for therapy. 1 We recently demonstrated that ABT-737 induces apoptotic cell death in a sub-group of MM at low nanomolar concentration (<150 n M ). 2 This sub-group of MM can be identified by its high Bcl-2/Mcl-1 Affymetrix gene expression ratio indicating that the expression level of Bcl-2 versus Mcl-1 mainly determines the susceptibility of myeloma cells to ABT-737 as previously demonstrated in other hematopoietic cells. 3 In addition, we have shown that Mcl-1 silencing strongly increases the sensitivity to ABT-737 of MM cells, highlighting the essential role of Mcl-1 in ABT-737 resistance. Although the orally active navitoclax has entered clinical trials and shown activity in hematological malignancies that are believed to be Bcl-2 dependent, the efficacy of this agent is limited by the thrombocytopenia caused by Bcl-x L inhibition. 4 To overcome this dose-limiting toxicity, ABT-199, the first-in-class orally bioavailable Bcl-2-selective BH3 mimetic, has been developed. Notably, it was reported that selective inhibition of Bcl-2 by ABT-199 demonstrated weak activity ex vivo on platelets. 5 These data were further extended to clinical observations. Indeed, ABT-199 showed promising antitumor activity while sparing platelets in chronic lymphoid leukemia patients. 5 Moreover, in a mouse model, ABT-199 also demonstrated in vivo efficacy against aggressive lymphoma without provoking thrombocytopenia. 6
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationKonopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Fernández de Larrea, C., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S., Vesole, D. H., Hajek, R., San Miguel, J. F., Sezer, O., Sonneveld, P., et al. (2013) · Leukemia · doi:10.1038/leu.2012.336 · Cited by 382
Self-citationVandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 191
Moreaux, J., Klein, B., Bataille, R., Descamps, G., Maiga, S., Hose, D., Goldschmidt, H., Jauch, A., Reme, T., Jourdan, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.033456 · Cited by 172
Self-citationLabi, V, Grespi, F., Baumgartner, F., & Villunger, A. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.37 · Cited by 165
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Lodé, L., Eveillard, M., Trichet, V., Soussi, T., Wuillème, S., Richebourg, S., Magrangeas, F., Ifrah, N., Campion, L., Traullé, C., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.023697 · Cited by 152
Self-citationABT-737 is highly effective against molecular subgroups of multiple myeloma
Bodet, L., Gomez‐Bougie, P., Touzeau, C., Dousset, C., Descamps, G., Maïga, S., Avet‐Loiseau, H., Bataille, R., Moreau, P., Gouill, S. L., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317438 · Cited by 126
Self-citation
Cited by
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
Self-citationEfficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788786 · Cited by 523
Self-citationTron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
Many players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421
Metadata
- Authors
- Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat-Deceunynck, C., & Amiot, M.
- Venue
- Leukemia
- Published
- 2013-07-17
- Volume
- 28
- Issue
- 1
- Pages
- 210-212
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2050702798
- Cited by
- 289
- References
- 10
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. https://app.cochat.ai/papers/10.1038/leu.2013.216
- The paper
- Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat-Deceunynck, C., & Amiot, M. (2014). The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. https://doi.org/10.1038/leu.2013.216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.